Quality of life among Iranian patients with beta-thalassemia major using the SF-36 questionnaire

Sao Paulo Medical Journal; Haghpanah, Sezaneh; Nasirabadi, Shiva; Ghaffarpasand, Fariborz; Karami, Rahmatollah; Mahmoodi, Mojtaba; Parand, Shirin; Karimi, Mehran.
São Paulo med. j ; 131(3): 166-172, 2013. tab
Artigo em Inglês | LILACS | ID: lil-679559

Documentos relacionados

  1. ß-Thalassemia Trait Caused by <i>SUPT5H</i> Defects: Another Case Report.
  2. CRISPR/Cas9, a promising approach for the treatment of ß-thalassemia: a systematic review.
  3. Adenine base editor-mediated correction of the common and severe IVS1-110 (G>A) ß-thalassemia mutation.
  4. The continuing global challenges of treating patients with beta-thalassemia.
  5. Efficacy and Safety of Gene Therapy for ß-Thalassemia.
  6. Defining curative endpoints for transfusion-dependent ß-thalassemia in the era of gene therapy and gene editing.
  7. Safety and efficacy of peripheral blood stem cells collection in healthy children and pediatric patients with thalassemia major weighing 20 kg or less.
  8. Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on ß654-Thalassemia.
  9. A synonymous variant is unmasked in thalassaemia.
  10. Prime editing: A potential treatment option for ß-thalassemia.